Announcements

On 28 June 2023, MDPI and the journal Cancers (ISSN: 2072-6694) organized a webinar Bone Metastasis in Breast Cancer. The aim of the webinar was to highlight some of the exciting, novel work that is currently being carried out by bone metastasis experts to address pertinent gaps in our knowledge.

It should be noted that 70–80% of patients with late-stage breast cancer will develop bone metastasis and this condition is currently incurable. Gaining a better understanding of how and why breast cancers preferentially spread to bone will help develop more effective treatments. In this webinar, we discuss new insights into factors that promote tumor cell colonization of and growth in the bone environment, including regulation of bone homing by miRNAs, the effects of vasculature and pro-inflammatory cytokines on metastatic outgrowth and immune cell regulation of tumor growth in the bone microenvironment.

Please note that this webinar is associated with a Special Issue in Cancers entitled “Bone Metastasis in Breast Cancer”.

You can watch the recorded webinar below:

Webinar Chair and Keynote Speakers:

• Prof. Dr. Penelope Dawn Ottewell, Department of Oncology and Metabolism, University of Sheffield, UK;
• Prof. Dr. Philippe Clézardin, INSERM, Research Unit UMR_S1033, LyOS, Faculty of Medicine Lyon-Est, France;
• Dr. Michelle McDonald, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia;
• Dr. Rachelle Whitney Johnson, Department of Medicine, Vanderbilt University Medical Center, USA.

MDPI will be attending the 64th Annual Spring Meeting of the Japanese Society of Clinical Cytology, which will be held from 9 to 11 June 2023 in Nagoya, Japan, at the Nagoya Congress Center.

The conference is the official annual meeting of the Japanese Society of Clinical Cytology (JSCC), which is an academic organization consisting of physicians specializing in cytology and cytotechnologists who perform cytology for the purposes of cancer diagnosis and screening. Physicians specializing in cytology that belong to the society include gynecologists, surgeons, internists, and pathologists as well as cytotechnologists.

In light of current trends, the theme of this annual meeting is “Be fascinated with the mastery of cytology!—Mastering the art and passing it on to the next generations”. Cytology is deeply related to cervical cancer screening in Japan. Raising the screening rate, improving and adhering to the screening management guidelines, including colposcopy, and increasing the vaccination rate are important issues for the eradication of cervical cancer. These preventive strategies for cervical cancer will be propagated in this meeting.

The following MDPI journals will be represented:

• Cells;
• Cancers;
• Diagnostics;
• Medicina;
• Medical Sciences.

Please do not hesitate to reach out (cells@mdpi.com) if you plan on attending this conference. Our delegates look forward to meeting you in person and answering any questions that you might have.

For more information about the conference, please visit the following website: https://www.c-linkage.co.jp/jscc2023/index.html.

We are pleased to announce the winners of the Cancers 2021 Best Paper Award. All papers published in 2021 in Cancers (ISSN: 2072-6694) were considered for the award. After a thorough evaluation of the originality and significance of the papers, citations, and downloads, four winners were selected. The winners will receive CHF 500, a certificate, and a chance to publish a paper free of charge after peer review in Cancers before the end of 30 December 2023.

Winning Reviews:

“PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer”
by Alessandro Rizzo, Angela Dalia Ricci and Giovanni Brandi
Cancers 2021, 13(3), 558; https://doi.org/10.3390/cancers13030558
Available online: https://www.mdpi.com/2072-6694/13/3/558

“STING Agonists as Cancer Therapeutics”
by Afsaneh Amouzegar, Manoj Chelvanambi, Jessica N. Filderman, Walter J. Storkus and Jason J. Luke
Cancers 2021, 13(11), 2695; https://doi.org/10.3390/cancers13112695
Available online: https://www.mdpi.com/2072-6694/13/11/2695

Winning Articles:

“LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia”
by Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. González-Rodríguez, Ángel R. Payer, Esther González-García, Alejandro López-Soto and Segundo Gonzalez
Cancers 2021, 13(9), 2112; https://doi.org/10.3390/cancers13092112
Available online: https://www.mdpi.com/2072-6694/13/9/2112

“The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab”
by Matteo Bauckneht, Carlo Genova, Giovanni Rossi, Erika Rijavec, Maria Giovanna Dal Bello, Giulia Ferrarazzo, Marco Tagliamento, Maria Isabella Donegani, Federica Biello, Silvia Chiola et al.
Cancers 2021, 13(13), 3117; https://doi.org/10.3390/cancers13133117
Available online: https://www.mdpi.com/2072-6694/13/13/3117

Please join us in congratulating the winners of the Cancers 2021 Best Paper Award. We would also like to take this opportunity to thank all of the authors who contributed to Cancers for their continued support.

Conference: 19^th Annual International Conference of the Metabolomics Society

Date: 18–22 June 2023

Place: Niagara Falls Convention Centre, 6815 Stanley Avenue, Niagara Falls, Ontario, Canada L2G 3Y9

Booth: #T12

MDPI will be attending the 19^th Annual International Conference of the Metabolomics Society, which will be held from 18 to 22 June 2023 in downtown Niagara Falls, Canada, at the Niagara Falls Convention Centre.

The conference is the official annual meeting of the Metabolomics Society, and the largest metabolomics meeting worldwide. It will cover the major scientific themes of: technology advances; computational metabolomics, statistics, and bioinformatics; metabolomics in health and disease; and metabolomics of plants, food, environment and microbes. A special theme for this conference will focus on mental health, drug addiction and medicinal cannabis. The scientific program will include plenary and keynote talks, three parallel scientific sessions, interactive poster sessions, sponsor lunches, other networking events and a specially organized parallel session to promote metabolomics research in industry. A strong line-up of both introductory and advanced workshops will take place on Sunday, 18 June, and the morning of Monday, 19 June. To complement the exciting scientific program, the conference will offer a welcome reception, vibrant early career events, a conference dinner and other engaging social activities.

The following MDPI journals will be represented:

• Metabolites;
• Agronomy;
• Antioxidants;
• Applied Biosciences;
• BioMed;
• BioMedInformatics;
• Biomolecules;
• Cancers;
• Cells;
• Children;
• CIMB;
• Diseases;
• Foods;
• Genes;
• JPM;
• Nutrients;
• Plants.

Please do not hesitate to reach out (metabolites@mdpi.com) if you plan on attending this conference. Our delegates look forward to meeting you in person and answering any questions that you might have.

For more information about the conference, please visit the following website: https://www.metabolomics2023.org/.

Conference: ATS (American Thoracic Society) Conference 2023
Date: 21–23 May 2023
Location: Washington DC, USA

MDPI will be attending ATS 2023 as an exhibitor; we welcome researchers from different backgrounds to visit and share their latest ideas with us.

This conference has been organized by the American Thoracic Society, and it will showcase the latest advances and discoveries in respiratory science, patient care and global respiratory health. At the conference, specialists will share and discuss the latest research and its applications to clinical, basic, and translational science in pulmonary, critical care, and sleep medicine.

The following MDPI journals will be represented:

• JCM;
• Medicina;
• Clinics and Practice;
• JPM;
• Cancers;
• Medicines;
• Healthcare;
• Metabolites;
• Children;
• Brain Sciences.

If you are planning to attend this conference, please do not hesitate to talk with us online. Our delegates look forward to meeting you in person at booth #2606, and answering any questions that you may have. For more information about the conference, please visit the following website: https://conference.thoracic.org/.

The list of relevant papers can be seen below:

“Diverse Roles and Targets of miRNA in the Pathogenesis of Testicular Germ Cell Tumour”
by Mrinal K.Das, Øyvind P. Haugen and Trine B. Haugen
Cancers 2022, 14(5), 1190; https://doi.org/10.3390/cancers14051190
Available online: https://www.mdpi.com/2072-6694/14/5/1190

“The Polymorphisms of Genes Encoding Catalytic Antioxidant Proteins Modulate the Susceptibility and Progression of Testicular Germ Cell Tumor”
by Uros Bumbasirevic, Nebojsa Bojanic, Marija Pljesa-Ercegovac, Marko Zivkovic, Tatjana Djukic, Milica Zekovic, Bogomir Milojevic, Boris Kajmakovic, Aleksandar Janicic, Tatjana Simic et al.
Cancers 2022, 14(4), 1068; https://doi.org/10.3390/cancers14041068
Available online: https://www.mdpi.com/2072-6694/14/4/1068

“Testicular Germ Cell Tumours and Proprotein Convertases”
by Aitziber Velado-Eguskiza, Laura Gomez-Santos, Iker Badiola, Francisco José Sáez and Edurne Alonso
Cancers 2022, 14(7), 1633; https://doi.org/10.3390/cancers14071633
Available online: https://www.mdpi.com/2072-6694/14/7/1633

“Transcriptional CDK Inhibitors as Potential Treatment Option for Testicular Germ Cell Tumors”
by Kai Funke, Robert Düster, Prince De-Graft Wilson, Lena Arévalo, Matthias Geyer and Hubert Schorle
Cancers 2022, 14(7), 1690; https://doi.org/10.3390/cancers14071690
Available online: https://www.mdpi.com/2072-6694/14/7/1690

“Comprehensive Analysis Identifies Ameloblastin-Related Competitive Endogenous RNA as a Prognostic Biomarker for Testicular Germ Cell Tumour”
by Tianxiang Geng, Catherine Anne Heyward, Xi Chen, Mengxue Zheng, Yang Yang and Janne Elin Reseland
Cancers 2022, 14(8), 1870; https://doi.org/10.3390/cancers14081870
Available online: https://www.mdpi.com/2072-6694/14/8/1870

“Genomic Profile in a Non-Seminoma Testicular Germ-Cell Tumor Cohort Reveals a Potential Biomarker of Sensitivity to Platinum-Based Therapy”
by Rodrigo González-Barrios, Nicolás Alcaraz, Michel Montalvo-Casimiro, Alejandra Cervera, Cristian Arriaga-Canon, Paulina Munguia-Garza, Diego Hinojosa-Ugarte, Nora Sobrevilla-Moreno, Karla Torres-Arciga, Julia Mendoza-Perez et al.
Cancers 2022, 14(9), 2065; https://doi.org/10.3390/cancers14092065
Available online: https://www.mdpi.com/2072-6694/14/9/2065

“Imaging of Pediatric Testicular and Para-Testicular Tumors: A Pictural Review”
by Anne-Laure Hermann, Aurore L’Herminé-Coulomb, Sabine Irtan, Georges Audry, Liesbeth Cardoen, Hervé J. Brisse, Saskia Vande Perre and Hubert Ducou Le Pointe
Cancers 2022, 14(13), 3180; https://doi.org/10.3390/cancers14133180
Available online: https://www.mdpi.com/2072-6694/14/13/3180

“Testicular Germ Cell Tumours—The Role of Conventional Ultrasound”
by Jane Belfield and Charlotte Findlay-Line
Cancers 2022, 14(16), 3882; https://doi.org/10.3390/cancers14163882
Available online: https://www.mdpi.com/2072-6694/14/16/3882

“Testicular Neoplasms: Primary Tumour Size Is Closely Interrelated with Histology, Clinical Staging, and Tumour Marker Expression Rates—A Comprehensive Statistical Analysis”
by Klaus-Peter Dieckmann, Hendrik Isbarn, Francesca Grobelny, Cansu Dumlupinar, Julia Utschig, Christian Wülfing, Uwe Pichlmeier and Gazanfer Belge
Cancers 2022, 14(21), 5447; https://doi.org/10.3390/cancers14215447
Available online: https://www.mdpi.com/2072-6694/14/21/5447

“An Overview of the Role of Multiparametric MRI in the Investigation of Testicular Tumors”
by Athina C. Tsili, Nikolaos Sofikitis, Ourania Pappa, Christina K. Bougia and Maria I. Argyropoulou
Cancers 2022, 14(16), 3912; https://doi.org/10.3390/cancers14163912
Available online: https://www.mdpi.com/2072-6694/14/16/3912

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office
Email: cancers@mdpi.com

April is designated as “Esophageal Cancer Awareness Month”, with various global activities that highlight and increase awareness of esophageal cancer for research support and development. We would like to take this opportunity to extend our appreciation to all the researchers who have contributed to the fight against this disease. In particular, we would like to share some of the high-quality and innovative research findings in the field of esophageal cancer, published in Cancers (ISSN: 2072-6694). We hope this announcement will provide useful information for this field.

The list of relevant papers can be seen below:

“Immunotherapy for Esophageal Cancer: State-of-the Art in 2021”
by Hugo Teixeira Farinha, Antonia Digklia, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer and Styliani Mantziari
Cancers 2022, 14(3), 554; https://doi.org/10.3390/cancers14030554
Available online: https://www.mdpi.com/2072-6694/14/3/554

“Intelligent Identification of Early Esophageal Cancer by Band-Selective Hyperspectral Imaging”
by Tsung-Jung Tsai, Arvind Mukundan, Yu-Sheng Chi, Yu-Ming Tsao, Yao-Kuang Wang, Tsung-Hsien Chen, I-Chen Wu, Chien-Wei Huang and Hsiang-Chen Wang
Cancers 2022, 14(17), 4292; https://doi.org/10.3390/cancers14174292
Available online: https://www.mdpi.com/2072-6694/14/17/4292

“The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer”
by Xin Wang, Nicolas L. Palaskas, Brian P. Hobbs, Jun-ichi Abe, Kevin T. Nead, Syed Wamique Yusuf, Joerg Hermann, Anita Deswal and Steven H. Lin
Cancers 2022, 14(5), 1304; https://doi.org/10.3390/cancers14051304
Available online: https://www.mdpi.com/2072-6694/14/5/1304

“cT1N0M0 Esophageal Squamous Cell Carcinoma Invades the Muscularis Mucosa or Submucosa: Comparison of the Results of Endoscopic Submucosal Dissection and Esophagectomy”
by Ching-Ya Wang, Bo-Huan Chen, Cheng-Han Lee, Puo-Hsien Le, Yung-Kuan Tsou and Cheng-Hui Lin
Cancers 2022, 14(2), 424; https://doi.org/10.3390/cancers14020424
Available online: https://www.mdpi.com/2072-6694/14/2/424

“The KEAP1-NRF2 System and Esophageal Cancer”
by Wataru Hirose, Hiroyuki Oshikiri, Keiko Taguchi and Masayuki Yamamoto
Cancers 2022, 14(19), 4702; https://doi.org/10.3390/cancers14194702
Available online: https://www.mdpi.com/2072-6694/14/19/4702

“Endoscopic Management for Post-Surgical Complications after Resection of Esophageal Cancer”
by Dörte Wichmann, Stefano Fusco, Christoph R. Werner, Sabrina Voesch, Benedikt Duckworth-Mothes, Ulrich Schweizer, Dietmar Stüker, Alfred Königsrainer, Karolin Thiel and Markus Quante
Cancers 2022, 14(4), 980; https://doi.org/10.3390/cancers14040980
Available online: https://www.mdpi.com/2072-6694/14/4/980

“Artificial Intelligence in the Management of Barrett’s Esophagus and Early Esophageal Adenocarcinoma”
by Franz Ludwig Dumoulin, Fabian Dario Rodriguez-Monaco, Alanna Ebigbo and Ingo Steinbrück
Cancers 2022, 14(8), 1918; https://doi.org/10.3390/cancers14081918
Available online: https://www.mdpi.com/2072-6694/14/8/1918

“Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma”
by William Jiang, Jelske M. de Jong, Richard van Hillegersberg and Matthew Read
Cancers 2022, 14(4), 996; https://doi.org/10.3390/cancers14040996
Available online: https://www.mdpi.com/2072-6694/14/4/996

“The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer”
by Cameron C. J. Lang, Megan Lloyd, Said Alyacoubi, Saqib Rahman, Oliver Pickering, Tim Underwood and Stella P. Breininger
Cancers 2022, 14(5), 1171; https://doi.org/10.3390/cancers14051171
Available online: https://www.mdpi.com/2072-6694/14/5/1171

“Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas”
by Christoph Treese, Jessica Werchan, Moritz von Winterfeld, Erika Berg, Michael Hummel, Lena Timm, Beate Rau, Ole Daberkow, Wolfgang Walther, Severin Daum et al.
Cancers 2022, 14(7), 1773; https://doi.org/10.3390/cancers14071773
Available online: https://www.mdpi.com/2072-6694/14/7/1773

“Neoadjuvant Carboplatin/Paclitaxel versus 5-Fluorouracil/Cisplatin in Combination with Radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Comparative Study”
by Xing Gao, Ping-Chung Tsai, Kai-Hao Chuang, Chu-Pin Pai, Po-Kuei Hsu, Shau-Hsuan Li, Hung-I Lu, Joseph Jan-Baptist van Lanschot and Yin-Kai Chao
Cancers 2022, 14(11), 2610; https://doi.org/10.3390/cancers14112610
Available online: https://www.mdpi.com/2072-6694/14/11/2610

“Management of Superficial Esophageal Squamous Cell Carcinoma and Early Gastric Cancer following Non-Curative Endoscopic Resection”
by Waku Hatta, Tomoyuki Koike, Kaname Uno, Naoki Asano and Atsushi Masamune
Cancers 2022, 14(15), 3757; https://doi.org/10.3390/cancers14153757
Available online: https://www.mdpi.com/2072-6694/14/15/3757

You are welcome to submit relevant papers to the journal Cancers.

Cancers Editorial Office
Email: cancers@mdpi.com

Conference: 29th Congress of the European Association for Cancer Research
Date: 12–15 June 2023
Place: Torino, Italy

MDPI will be attending the 29th Congress of the European Association for Cancer Research, held in Torino, Italy, from 12 to 15 June 2023. This conference aims to achieve an in-depth exchange of the latest research results in the field of basic research, clinical application, cutting-edge technology, and industrial development in the field of cancer research over the year. During this conference, MDPI will welcome researchers from different backgrounds to visit and share their latest ideas with us.

The following MDPI journals will be represented:

• Cells;
• Cancers;
• Children;
• CIMB;
• Current Oncology;
• Diagnostics;
• Geriatrics;
• Healthcare;
• JCM;
• Medical Sciences.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://www.eacr2023.org/.

Conference: The 112th Annual Meeting of the Japanese Society of Pathology
Date: 13–15 April 2023
Place: Shimonoseki, Japan

MDPI will be attending the 112th Annual Meeting of the Japanese Society of Pathology as an exhibitor. This meeting will be held in Shimonoseki, Japan, from 13 to 15 April 2023. This conference is held every year, and the theme of the 112th edition is “Doors to Overcoming Intractable Diseases: Potential of Pathology and Pathological Diagnostics”. The aim of this meeting is to provide an opportunity for all the members who chose the path of pathology to engage in hot discussions and introduce new perspectives to pathology and diagnostic pathology.

The following MDPI journals will be represented:

• Cancers;
• Diagnostics;
• JPM;
• Pathogens;
• CIMB;
• Pathophysiology.

If you are attending this conference, please feel free to start a conversation with us. Our delegates look forward to meeting you in person and answering any questions that you may have. For more information about the conference, please visit https://site2.convention.co.jp/112jsp/english/.

We are delighted to announce one of the winners of the Cancers 2022 Best Ph.D. Thesis Award— Dr. Adria Cañellas Socias, from the University of Barcelona, Spain, for his thesis entitled “Metastatic Recurrence in Colorectal Cancer Arises from Residual EMP1+ Cells”.

We have received a large number of excellent essays from Ph.D. students and postdocs. We would like to thank the award committee for their excellent work in the hard task of selecting winners from such excellent candidates, as well as everyone who participated in this award and helped make it a huge success!

The winners will receive CHF 800, a certificate, and a chance to publish a paper free of charge after peer review in Cancers (ISSN: 2072-6694) before the end of 2023.